About Seaport Therapeutics Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://seaporttx.com
Frequently Asked Questions
What is the 52-week range for SPTX?
The 52-week high is $28.3833 and the 52-week low is $14.85.
What is the P/E ratio for SPTX?
The P/E ratio data is currently unavailable.
What is the dividend yield for SPTX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
ROE data is currently unavailable.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
P/B ratio data is currently unavailable.
Analyst Recommendation Trends
Wall Street analyst consensus for SPTX over the last few months:
Latest SPTX News
This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated bullish coverage on TSEM, PGEN, SPTX, PDFS and CF, setting targets of $300, $12, $46, $60 and $162.
Raymond James Initiates Coverage On Seaport Therapeutics with Strong Buy Rating, Announces Price Target of $46
Raymond James analyst Tiago Fauth initiates coverage on Seaport Therapeutics (NASDAQ:SPTX) with a Strong Buy rating and announces Price Target of $46.
PureTech Health PLC (PTCHF) (H1 2026) Earnings Call Highlights: Cash Runway to 2028, Seaport's ...
PureTech Health PLC (PTCHF) ended H1 2026 with $220 million in cash, cut go-forward burn to $30--$40 million annually, and is running ahead of its target of three concept-stage programs per year.
PureTech Health H1 Earnings Call Highlights
PureTech Health (NASDAQ:PRTC) outlined progress across its portfolio in its 2026 half-year results call, highlighting external financings for Celea Therapeutics and Seaport Therapeutics, regulatory progress at Gallop Oncology, and a strategy centered on earlier external funding for its founded entit
Seaport Therapeutics to Participate in September Investor Conferences
BOSTON, September 14, 2026--Seaport Therapeutics, Inc. (Nasdaq: SPTX) ("Seaport" or the "Company"), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in a series of additional upcoming investor conferences in September, including a company presentation and panel discussion featuring Co-Founder and Chief Executive Officer, Daphne Zohar, at the Goldman Sachs Life Sciences Sym
HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Seaport Therapeutics (NASDAQ:SPTX) with a Buy and maintains $50 price target.
PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
BOSTON, September 09, 2026--PureTech Founded Entity Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo in Healthy Volunteers
Seaport Therapeutics, Inc. (SPTX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Seaport Therapeutics, Inc. (SPTX) Citigroupâs Biopharma Back to School Summit 2026 September 9, 2026 1:00 PM EDTCompany ParticipantsLauren White - Chief...
Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
BOSTON, September 09, 2026--Seaport Therapeutics Reports Positive Topline Results from Phase 1 Driving Simulation Trial of GlyphAllo™ in Healthy Volunteers
Seaport Therapeutics Reports Phase 1 Results; GlyphAllo At 375 mg Meets Primary Endpoint With No Driving Impairment; 250 mg Dose Also Achieves Key Secondary Endpoint
Trial met its primary endpoint, showing that evening dosing of GlyphAllo at 375 mg did not impair next-morning driving performance compared to placebo on Day 5, following multiple-day dosingKey secondary endpoint also
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-22 | HOMBACH ROBERT J. | +13,000 | $18.136 | $235,768 |
| 2026-05-04 | PureTech Health plc | -3,031,578 | - | - |
| 2026-05-04 | PureTech Health plc | -8,421,052 | - | - |
| 2026-05-04 | PureTech Health plc | -40,000,000 | - | - |
| 2026-05-04 | PureTech Health plc | +965,255 | - | - |
| 2026-05-04 | PureTech Health plc | +2,681,265 | - | - |
| 2026-05-04 | PureTech Health plc | +12,736,014 | - | - |
| 2026-05-04 | Gladstein Lana | -105,263 | - | - |
| 2026-05-04 | Gladstein Lana | +33,515 | - | - |
| 2026-05-04 | Chen Michael Cunyuan | -10,526 | - | - |
| 2026-05-04 | Chen Michael Cunyuan | +3,351 | - | - |
| 2026-05-04 | White Lauren | -21,052 | - | - |
| 2026-05-04 | White Lauren | +6,702 | - | - |
| 2026-05-04 | Torres Denice | -42,105 | - | - |
| 2026-05-04 | Torres Denice | +13,406 | - | - |
| 2026-05-04 | Loebel Antony | -63,157 | - | - |
| 2026-05-04 | Loebel Antony | +20,109 | - | - |
| 2026-05-04 | HEALY JAMES | -2,526,315 | - | - |
| 2026-05-04 | HEALY JAMES | -6,052,631 | - | - |
| 2026-05-04 | HEALY JAMES | +804,379 | - | - |
| 2026-05-04 | HEALY JAMES | +1,927,159 | - | - |
| 2026-05-04 | PAUL STEVEN M | -210,526 | - | - |
| 2026-05-04 | PAUL STEVEN M | +67,031 | - | - |
| 2026-05-04 | CRANDELL KEITH | -2,681,265 | - | - |
| 2026-05-04 | CRANDELL KEITH | -2,513,686 | - | - |
| 2026-05-04 | CRANDELL KEITH | +1,100,000 | $18 | $19,800,000 |
| 2026-05-04 | CRANDELL KEITH | +2,681,265 | - | - |
| 2026-05-04 | CRANDELL KEITH | +2,513,686 | - | - |
| 2026-04-30 | Gladstein Lana | +63,680 | - | - |
| 2026-04-30 | Chen Michael Cunyuan | +63,680 | - | - |
| 2026-04-30 | White Lauren | +63,680 | - | - |
| 2026-04-30 | Torres Denice | +12,258 | - | - |
| 2026-04-30 | Loebel Antony | +63,680 | - | - |
| 2026-04-30 | Wheadon David E. | +12,258 | - | - |
| 2026-04-30 | Zohar Daphne | +1,486,786 | - | - |
| 2026-04-30 | Zohar Daphne | +271,813 | - | - |
| 2026-04-30 | Mates Sharon | +49,033 | - | - |
| 2026-04-30 | HOMBACH ROBERT J. | +12,258 | - | - |
| 2026-04-30 | PAUL STEVEN M | +991,192 | - | - |
| 2026-04-30 | PAUL STEVEN M | +12,258 | - | - |
| 2026-04-30 | PETERSON SANDRA E | +12,258 | - | - |